Swiss Re's August 2025 Life Guide update provides U.S. life insurers with new underwriting guidance on repurposed longevity drugs like metformin and rapamycin, enhancing risk assessment for evolving health trends.

Swiss Re updates its Life Guide to help underwriters assess life insurance risks related to repurposed longevity drugs like metformin and rapamycin, enhancing medical risk evaluation and underwriting consistency across global markets.